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Liver transplantation across ABO 
blood groups 
Robert D. Gordon, M.D., Shunzaburo Iwatsuki, M.D., Carlos O. Esquivel, M.D., Ph.D., 
Andreas Tzakis, M.D., Satoru Todo, M.D., and Thomas E. Starzl, M.D., Ph.D., 
Pittsburgh, Pa. 
Six hundred seventy-one first, second, and third orthotopic liver allografts in 520 
patients were reviewed to determine the effect of donor-recipient mismatches or 
incompatibilities for the ABO blood groups on graft survival. A significant advantage 
for ABO donor-recipient identity was found, especially in adults and for first grafts. 
However, a surprisingly large number of ABO incompatible grafts were successful. We 
recommend that nonidentical or incompatible grafts be limited to patients such as 
small children for whom the supply of available donors is severely limited or for 
patients in urgent need of transplantation or retransplantation. 
From the Department oj Surgery, Universzty Health Center oj Pittsburgh, University oj 
Pittsburgh, and the Veterans Administration Medical Center, Pittsburgh, Pa. 
MORE THAN 20 years ago the importance was demon-
strated in renal transplantation of avoiding placement 
of kidney grafts into recipients possessing preformed 
antidonor antibodies. The first preformed antibody 
system to be studied thoroughly was that of the ABO 
isoagglutinins,l and not long after the threat posed by 
cytotoxic antibodies was appreciated.2. 3 With either 
type of recipient antibody, hyperacute rejection 
occurred at a high rate. Observance of ABO blood 
group compatibility rules and avoidance of positive 
lymphocytotoxic cross-matches have been the most 
universally used immunologic criteria for selection of 
recipients of renal allografts. 
The extent to which these guidelines apply to other 
organs has not been completely delineated. In past 
publications,4.6 we have pointed out that the liver is 
resistant to hyperacute rejection from either type of 
antibody. However, no extensive study has been 
reported in recent years of high survival after liver 
transplantation about the effect, if any, of ABO com-
patibility on outcome. In addition, recent attention has 
been focused on a special kind of graft versus host 
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reaction caused by anti host isoagglutinin production by 
liver grafts that are compatible with liver recipients but 
of a different ABO type.7 
In this article we have reviewed 672 transplants in 
520 patients performed between March 1, 1980, and 
Dec. 31, 1985, in an effort to determine if the outcome 
of liver transplantation is influenced by ABO confor-
mity, compatibility, and incompatibility between donor 
and recipient. 
MATERIAL AND METHODS 
Case material. Five hundred twenty patients 
received 672 orthotopic liver allografts between March 
1, 1980, and Dec. 31, 1985. All patients have been 
followed through Jan. 31, 1986 (Table I). Actuarial 
patient the and graft survivals were calculated by life 
table method.8. 9 The age range of the patients was 4 
months to 67 years (mean, 25.3 ± 18.1, SD years), 
including 310 adults given 387 grafts and 210 children 
given 285 grafts. There were 520 primary grafts, 124 
second grafts, and 27 third grafts. 
One pediatric patient received a fourth transplant 
during this period. The graft was from an ABO 
matched donor, and to date the patient has survived 
with this graft. This is the only graft not included in the 
statistics here reported. 
All patients were treated with cyclosporine and 
prednisone as described elsewhere. 1o Since December 
1983, OKT3 monoclonal antibody (Ortho Pharmaceu-
ticals, Raritan, N.].) has been given for brief periods 
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Table 1. Adult and pediatric transplants classified by ABO match 
ABO Class Failed (%) .Functlonlng (%) Total 
Adult grafts 181 (46.8) 206 (53.2) 387 
ABO Identical 142 (43.2) 187 (56.8) 329 
ABO Compatible 33 (66.0) 17 (34.0) 50 
ABO Incompatible 6 (75.0) 2 (25.0) 8 
Pediatric grafts 139 (48.9) 145 (51.1) 284 
ABO Identical 102 (46.4) 118 (53.6) 220 
ABO Compatible 23 (56.1) 18 (43.9) 41 
ABO Incompatible 14 (60.9) 9 (39.1) 23 
Totals 320 (47.7) 351 (52.3) 671 
ABO Identical 244 (44.4) ,305 (55.6) 549 
ABO Compatible 56 (61.5) 35 (38.5) 91 
ABO Incompatible 20 (64.5) 11 (35.5) 31 
Table II. First, second, and third transplants classified by ABO match 
ABO Class Failed (%) 
First grafts 222 (42.7) 
ABO Identical 179 (40.0) 
ABO Compatible 35 (58.3) 
ABO Incompatible 8 (61.5) 
Second grafts 83 (66.9) 
ABO Identical 57 (67.9) 
ABO Compatible 15 (62.5) 
ABO Incompatible 11 (68.8) 
Third grafts 15 (55.6) 
ABO Identical 8 (44.4) 
ABO Compatible 6 (85.7) 
ABO Incompatible 1 (50.0) 
Total 320 (47.7) 
(10 to 21 days) to about 75 patients for treatment of 
acute cellular rejection or during periods of reduced 
cyclosporine coverage. 11 
Cirrhosis was the indication for liver replacement in 
133 (25.6%) of the patients. This group consisted 
mainly of patients with chronic aggressive hepatitis or 
cryptogenic cirrhosis and included a small number of 
patients with alcoholic cirrhosis. Biliary atresia was the 
reason for transplantation in 107 (20.6%) patients and 
accounted for more than half of the transplantations 
performed in children. Other indications for transplan-
tation were primary biliary cirrhosis in 89 patients 
(17.1 %), inborn errors of metabolism in 68 (13.1 %) 
patients, sclerosing cholangitis in 42 (8.1%) patients, 
and primary liver tumors in 20 (3.9%) patients. 
Sixty-one (11.7%) primary grafts were done for other 
indications, including acute hepatic necrosis, familial 
cholestasis, neonatal hepatitis, secondary biliary cir-
rhosis, and trauma. 
Functioning (%) Total 
298 (57.3) 520 
268 (60.0) 447 
25 (41.7) 60 
5 (38.5) 13 
41 (33.1) 124 
27 (32.1) 84 
9 (37.5) 24 
5 (31.2) 16 
12 (44.4) 27 
10 (55.6) 18 
1 (14.3) 7 
1 (50.0) 2 
351 (52.3) 671 
Donor-recipient matching. Recipients were select-
ed on the basis of medical need, estimated liver size and 
body weight, and ABO blood group. Histocompatibili-
ty antigen typing and lymphocytotoxic cross-matching 
were done retrospectively and played no role in recipi-
ent selection. We have continued to transplant prefer-
entially between ABO identical donors and recipients 
except for very small children, for whom the supply of 
available organs is severely limited and for patients in 
perilous condition. 
RESULTS 
Patient survival. Actuarial survival for the 520 
patients is presented in Fig. 1, A and is 69.3% at 1 year 
and 60.80/0 at 5 years. Survival for children (under 19 
years old) is 70.20/0 at 1 year and 67.6% at 5 years 
compared with 68.60/0 at 1 year and 55.1 % at 5 years 
for adults. There is no significant difference in the 
actuarial curves for children and adults (Fig. 1, B). 
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Fig. 1. A, Actuarial survival for 520 patients and 671 first, 
second, and third grafts. B, Actuarial survival of 210 
pediatric and 310 adult graft recipients. Pediatric recipients 
were 18 years of age or under at the time of transplantation. 
C, Actuarial survival of 520 graft recipients according to 
recipient ABO blood type. There is no significant difference 
in survival among the four groups. 
There is also no significant difference in patient 
survi val based on recipient ABO blood group (Fig. 1, 
C). 
Graft survival. Actuarial survival for all 671 grafts 
is shown in Fig. 1, A. One-year survival is 53.7% and 
5-year survival is 44.4%. 
Each transplantation was classified as an ABO 
identical graft (ABO identity between donor and 
recipient), an ABO compatible but nonidentical graft 
(0 to any non-O, A, or B to AB), or an ABO 
incompatible graft (A to B, B to A, B or A to 0, or AB 
to any non-AB)o The results to date are summarized in 
Table I, and actuarial graft survival out to 3 years on 
the basis of ABO donor-recipient match is shown in 
Fig. 2, A. Beyond 3 years for compatjble grafts and 2 
years for incompatible grafts, the sample sizes are 
usually too small for valid comparisons. Survival of 
grafts with ABO identity is significantly better than 
that of compatible but nonidentical grafts (p < 0.01) 
and incompatible grafts (p < 0.03). 
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Fig. 2. A, Actuarial graft survival based on donor-recipient 
ABO matching. B, Actuarial graft survival for first, second, 
and third transplants. Primary graft survival is significantly 
better than survival for retransplanted grafts. 
Graft survival is stratified for pediatric and adult 
patients with transplaqts in Table 1. Three hundred 
fifty-one (52.3%) grafts are functioning, including 145 
(51.1 %) in children and 206 (53.2%) in adults. Actuar-
ial survival for pediatric and adult patients with grafts 
is shown in Fig. 3. Survival for ABO identical pediatric 
patients with grafts. (Fig. 3, A) is not different from 
that for patients with compatible but nonidentical 
grafts (Fig. 3, B). Survival of pediatric patients with 
ABO identical grafts (Fig. 3, A) is better (p < 0.02) 
than that for pediatric patients with incompatible 
grafts (Fig. 3, C) out to 2 years, but this finding should 
be interpreted cautiously since the sample size of 
incompatible grafts is small. 
Actuarial survival of ABO identical grafts in adults 
(Fig. 3, A) is significantly better than for either adults 
with compatible but nonidentical (p < 0.01, Fig. 3, B) 
or incompatible grafts (p < 0.05, Fig. 3, C). 
Survival of first, second, and third grafts is summa-
rized in Table II. Fifty-seven percent of first grafts, 
33% of second grafts, and 44% of third grafts have 
survived. Actuarial survival of primary grafts versus 
retransplants is shown in Fig. 2, B. Primary graft 
survival is significantly better than survival of second 
grafts (p < 0.001) and is significantly better out to 2 
years (p < 0.04) compared with third grafts. 
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Fig. 3. Actuarial survival for pediatric and adult ABO 
identical (A), compatible but nonidentical (B), and incom-
patible (C) grafts. ABO identical grafts in adults (A) are 
significantly better than compatible (B) or incompatible (C) 
adult grafts. 
Actuarial survival for first grafts and retransplants 
according to ABO matching is presented in Fig. 4. 
Primary ABO identical grafts (Fig. 4, A) have survived 
significantly better than ABO compatible but noniden-
tical grafts (p < 0.01, Fig. 4, B). The better results 
with primary ABO identical grafts versus ABO incom-
patible grafts (Fig. 4, C) approaches statistical signifi-
cance (p < 0.10) but is liipited by small sample size. 
The factor of clinical' need. An urgent factor 
existed in the vast majority of recipients given other 
than ABO identical grafts. Of the 31 incompatible 
livers, 18 were used for retransplantation (Table III). 
Most of the other three livers were transplanted to 
patients whose needs were also great. Only two of the 
adults and 11 of the children received an ABO incom-
patible transplant under elective conditions. The scar-
city of small donors was the reason for the more 
frequent acceptance of mismatched pediatric organs. 
The urgency factor and the use of incompatible 
organs in tiny recipients made discriminating assess-
ment difficult of the role of ABO matching, particular-
ly since the difficulties in controlling rejection were so 
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Fig. 4. Actuarial survival for first, second, and third ABO 
identical (A), compatible (B), and incompatible grafts (C). 
Graft survival for identical primary grafts (A) is significant-
ly better than survival for compatible primary grafts (B). 
variable. Fig. 5 presents the postoperative course after 
a primary B to A liver transplant in a 9 kg, 2-year old 
boy with ai-antitrypsin deficiency. The liver func-
tioned well starting on the day of surgery, and the 
patient was discharged from the hospital 23 days later 
after an uneventful recovery. He continues to do well 
17 months after transplantation. 
The other end of the spectrum is shown in Fig. 6. A 
desperately ill 5-year-old girl with blood type B with 
biliary atresia was given the liver of a blood type A 
donor. After surgery moderate rise increases in trans-
aminase levels were typical of moderate but reversible 
ischemic injury. However, the bilirubin level rose 
quickly during the first week and remained elevated. 
An arteriogram obtained 5 days after transplantation 
showed patent vessels. High-dose prednisone resulted 
only in transient improvement. Repeat angiography on 
day 15 showed severe "pruning" of arteries in the liver 
characteristic of severe rejection. Transaminase levels 
rose sharply between days 18 and 21. A biopsy 
specimen obtained at this point showed only massive 
hepatic necrosis. Death occurred on day 27. 
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Fig. 5. Clinical course after transplantation of a primary 
type-B liver graft to a type-A 2-year-old child with al-
antitrypsin deficiency, which demonstrates uneventful recov-
ery after ABO incompatible transplantation. (IV, intrave-
nous: PO, by mouth; WBC, white blood count; SCOT, serum 
glutamic-oxaloacetic transaminase; SePT, serum glutamic-
pyruvic transaminase.) 
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Fig. 6. Clinical course after transplantation of a primary 
type-A liver to a type-B 5-year-oid child with biliary atresia, 
which demonstrates progressive graft failure and death 27 
days after transplantation of an ABO incompatible graft. (IV, 
intravenous; PO, by mouth; WBC, white blood count; 'SCOT, 
serum glutamic-oxaloacetic transaminase; SePT, serum glu-
tamic-pyruvic transaminase.) 
Table llI. Outcome according to urgency of transplantation of ABO incompatible grafts 
Failed Functioning Patient Patient 
graft 
Adults 6 
Elective 0 
Urgent 6 
Children 13 
Elective 6 
Urgent 7 
Double immunologic jeopardy. In both of the 
foregoing cases there was double jeopardy from immu-
nologic factors. The grafts, which were confronted with 
preformed antigraft isoagglutinins, were capable in 
turn of producing isoagglutinins that could lyse recipi-
ent red blood cells.7 Such bidirectional immunologic 
risk can occur with A to B or B to A transplants. These 
risks were accepted in 14 patients, including six of the 
graft 
2 
1 
10 
5 
5 
alive dead 
2 6 
0 
1 6 
12 11 
6 5 
6 6 
retransplantations. In eight patients, the results were 
good, and in the other six the grafts failed or the 
patients died soon after transplantation. Obvious 
hemolysis was not diagnosed in any of the patients. 
DISCUSSION 
The hyperacute rejection of renal allografts in 
patients who receive kidneys from incompatible donors 
--_._----------------------_. 
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with ABO blood group has been well described. I • 12 
Such grafts do not sustain an effective renal blood flow, 
and angiography reveals that the small vessels of the 
excised kidneys are closed. Histopathologically the 
arterioles and capillaries are plugged with formed 
blood elements, particularly erythrocytes and plate-
lets. 
The blood group substances that allow red cells to be 
typed are found in other tissues, including the kidney 
and liver,13, 14 and these tissues will bind naturally 
occurring anti-A or anti-B isoagglutinins if transplant-
ed into an ABO incompatible recipient. I However, 
hyperacute rejection of kidneys does not automatically 
follow, and some of the longest surviving kidney grafts 
in the world have been across ABO blood groups, 
including one of our A-type patients treated more than 
23 years ago who still has perfect function of his B-type 
kidney. The expected incidence of hyperacute rejection 
of incompatible kidneys is not known, Recently Alex-
andre et al. I5 have shown that removal of ABO 
isoagglutinins by plasmapheresis and drug pretreat-
ment can permit the reliable transplantation of kidneys 
across ABO barriers. The studies of Rapaport et al. t6 
showing that the ABO system is a histocompatibility 
determinant have suggested possible increased late 
hazard even for grafts that survive early, but this 
conjecture has not been proved. 
The liver has been regarded as a privileged organ 
able to be transplanted across ABO barriers witbout 
suffering hyperacute rejection4-6 from antigraft anti-
bodies. With livers a different kind of complication has 
occurred in patients after transplantation from compat-
ible donors of different ABO types. Examples are 0 to 
A, B, or AB; A to AB; or B to AB. In such cases the 
production by the graft of anti-A or anti-B antibodies 
directed against the host has caused hemolytic anemia 
12 to 21 days after transplantation.? The hemolytic 
anemia is usually self-limited and mild. However, no 
serious examination has been reported of the influence 
on the results of the transplanting of ABO compatible 
but nonidentical livers. 
In this article the possible disadvantages of ABO 
nonconformity have been examined in a large series of 
consecuti ve orthotopic liver transplantations under 
cyclosporine and prednisone immunosuppression. The 
data have shown a significant advantage for ABO 
identical grafts, especially for primary grafts and grafts 
used in adults. Thus our policy will continue to be to 
search for ABO identity in our donor-recipient pair-
ing. 
However, the success rate with transplantation from 
ABO nonidentical or even incompatible donors has 
Liver transplantation across ABO blood groups 347 
been substantial. Patients needing retransplantation 
are more likely to receive a graft under urgent circum-
stances in which whatever the penalties may be of an 
ABO mismatch or ABO incompatibility, these may be 
less than the alternatives of graft sepsis, coagulopathy, 
depression of the central nervous system, and metabolic 
derangements. 
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DISCUSSION 
Dr. Rupins (Irvine, CaliL). This is fascinating work. I was 
a little concerned in terms of how you viewed your data on 
your graphs. It seemed to me that most of the losses you have 
in your transplant group occurred within the first 6 months, 
about 90% I would say. It also seems that the ABO groups 
demonstrate a clear advantage in the matching, as you 
pointed out. Thus it would seem that ABO is very important 
in 6-month survival of the graft, and I wondered if you 
analyzed your data at 6 months and is that significant? 
Dr. Nancy Ascher (Minneapolis, Minn.). It is incredible 
the amount of data that you have analyzed. However, I have 
several questions. Have you been measuring antibody levels 
in the patients who are going to receive ABO incompatible or 
mismatched grafts? The group from Belgium who have used 
ABO incompatible kidney grafts suggest plasmaphoresis or 
the use of ALG. They advocate the measurement of the 
antibody level so that you can monitor the titers and 
determine when plasmaphoresis is necessary. We have per-
formed four grafts across ABO incompatibilities, all As to Os, 
without any untoward event. We have also followed their 
advice of performing splenectomy at the time of transplant. A 
second question is whether you analyzed the A to 0 groups or 
the A subtypes? As you know, individuals with A-type blood 
can now be divided into two groups; 80% of the individuals 
are A-1 and 20% are A-2. Individuals who are A-2 will not 
elicit any antibody response in 0 recipients; thus that is 
another factor that has to be evaluated. Finally, do you have a 
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matched group of individuals who received ABO mismatched 
livers and individuals who received matched livers, according 
to severity of disease? I am troubled by the poor results in the 
individuals in whom you are hard pressed to find a liver, 
forcing you to cross blood group barriers. 
Dr. Gordon (closing). Dr. Rupins, the life table survival 
curves were analyzed with the log rank X' method. We also 
calculated z scores for each interval of observation. As you 
might expect, the sample sizes available at 6 months are large 
for most populations studied and therefore the differences 
observed are highly significant at the 6-month interval. 
Dr. Ascher, the use of plasmapheresis to remove preformed 
anti-ABO blood group antibody has special relevance for 
kidney transplantation, since it might permit transplantation 
across ABO barriers in a situation that is otherwise usually 
prohibitive. However, we know that the ABO blood groups 
are not prohibitive in most circumstances for liver transplan-
tation. We have not measured levels of preformed antibody 
before transplantation, but I agree that it would be worth-
while to correlate such measurements with outcome. 
The poorer results we see with patients for whom ABO 
blood groups are crossed because of urgent need probably 
reflect medical circumstances and patient selection rather 
than a pronounced effect of ABO immunity. Nonetheless, we 
cannot be certain of this in every case and further study is 
needed. The difficulty, of course, is that liver transplantation 
occurs in such a complex setting that analysis is often 
difficult. 
The A-2 subtype is a small percentage of patients, and 
even in a series of liver transplantations as large as this one, 
whel} we begin to subdivide at the level of ABO subtypes, the 
sample sizes get too small for meaningful analysis. We will 
require a larger study to address this interesting question. 
